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ABSTRACT
Glutathione S-transferase GSTπ has been one of the significant targets for cancer treatment in the 
past several years. The reason behind that is 1) its overexpression in some cancer cells compared 
to normal ones 2) its ability to cause resistance against cancer chemotherapeutics and 3) its 
protective role against reactive oxygen species (ROS). We have synthesized a large number of 
compounds which have strong potency against different cancer cell lines. These compounds 
possess a 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore. In the present study some 
investigations as to the way in which cytotoxicity is mediated was undertaken. Our results have 
demonstrated that the analogs NC 2067 and NC 2081 behaved as substrates for GSTπ and 
reduced the level of GSH. This was apparent by the decrease in the concentrations of both 
compounds after the addition of GSTπ and GSH. In addition, both agents caused about 3-7 folds 
increase in ROS levels. The dichlorodihydrofluorescein dye was used for this purpose due to its 
fluorescence characteristic after being oxidized by ROS. High levels of these species cause a 
drop in the mitochondrial membrane potential. This phenomenon was detected when the 
monomeric form of JC-1 levels were increased after treatment. The reduction of 2-3 folds was 
seen when the cells were treated with the IC50 values of both compounds. In addition, both 
agents inhibited oxygen consumption implicating their ability to inhibit oxidative 
phosphorylation. We also evaluated  the effect of both agents on mitochondrial swelling. NC 
2081 caused swelling using concentrations of 10 µM and 50 µM. This was apparent when the 
absorption of an isolated rat liver mitochondrial solution decreased after the addition of the 
compound. The addition of the higher concentration caused about 2 fold greater effect than the 
lower one. On the other hand, compound NC 2067 produced minimal swelling only at a 
concentration of 50 µM.
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11. INTRODUCTION
Cancer is recognized as one of the main causes of death. Numerous efforts have been
taken to study the biochemical differences between cancer and normal cells in order 
to design agents that would have the ability to treat this disease. In the past decades, 
these efforts resulted in new agents finding their place into clinical practice. Both 
pharmacological and non-pharmacological approaches are used in cancer treatment, 
each associated with significant limitations. One major drawback of the currently 
available pharmacological approaches is the serious adverse effects accompanying 
the use of anticancer drugs, due mainly to their potential to harm normal cells and 
not just malignant ones. Consequently, there is an urgent need to identify new agents 
that have the ability to target cancer cells and have minimal or no effects on normal 
healthy cells. The established differences in the biochemical behavior of both cell 
types have made such options achievable. 
In this thesis work I investigated two novel cytotoxic agents, namely, 1-[4-[2-
dimethylaminoethoxy]phenylcarbonyl]-3,5-bis[phenylmethylene]-4-piperidone 
hydrochloride (NC 2067) and 1-[4-{2-[4-morpholinyl]ethoxy}phenylcarbonyl]-3,5-
bis[phenylmethylene]-4-piperidone hydrochloride hemihydrate (NC 2081) for their
ability to selectively inhibit the growth of cancer cells and to understand their
mechanisms of action. 
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Figure 1.1: A. The structure of NC 2067, B. The structure of NC 2081
32. BACKGROUND
2.1 Cancer biology 
Cancer is characterized by the abnormal growth of cells that tend to proliferate
continuously without control. (Kleinsmith, 2006). In the United States it is estimated 
that one out of four deaths is due to cancer (Jemal et al., 2007). Cancer is now 
recognized as the leading cause of death in Canada according to the Canadian Cancer 
Society (Canadian cancer statistics, 2011)
 Cancers are formed from cells that have a defective DNA structure, which leads to 
abnormality in the function(s) and reproduction of cells. It is generally accepted that 
a single abnormality in one of these events is insufficient to cause cancer (Croce, 
2008) since cancer is a multi-step process. Genetic abnormalities may occur in proto-
oncogenes, which regulate cell growth, or tumor suppressor genes which normally 
favor growth inhibition. Mutations that lead to an induction in the activity of proto-
oncogenes, or inhibition of the tumor suppressor genes, are initial steps for cancer 
development. Examples of oncogenes include transcription factors, growth factors, 
growth factor receptors and apoptosis regulators. Tumor suppressor genes function 
alongside proto-oncogenes but with an opposite effect. Such genes tend to suppress 
cell division when DNA is damaged until it is repaired. If repair is not possible, 
tumor suppressor genes such as p53 induce apoptosis (Croce, 2008). Cancer cells can 
also be classified into malignant or benign forms. Malignant cancers have the ability 
to invade and destroy other cells and even undergo metastasis to other parts of the 
4body, whereas benign tumors grow only in specific locations and have a lower 
possibility to invade other tissues.
2.2 Cancer treatment methods
In clinical practice, physicians use regimens that combine two or more 
methods/drugs for cancer treatment. Different approaches are usually needed in order
to give maximal potency against cancer cells while minimizing drug resistance and 
adverse effects. The usual treatment approaches for cancer include surgery, 
radiotherapy, hormonal therapy, immunotherapy and chemotherapy.
2.2.1    Hormonal therapy
Certain types of cancer cells require specific hormones to grow. Estrogen for 
example is involved in the pathogenesis of estrogen receptor positive (ER+) breast 
cancer. Treatment options for such cancers involve blocking estrogen receptors by 
tamoxifen (Zilli et al., 2009), which has been a mainstay therapy for post-
menopausal women having breast cancer for many years (Zilli et al., 2009). Another 
type of hormone-dependent cancer is prostate cancer which depends on androgens
for its development. For this reason, androgenic blockers are used as a treatment 
method for prostate cancer. It is evident that blocking these receptors by agents such 
as flutamide can be used as a first line therapy for prostate cancer which is effective 
by regulating its growth (Beekman and Hussain, 2008).
52.2.2    Anti-Angiogenesis therapy
Angiogenesis is the process of new blood vessel development. This phenomenon 
normally occurs normally during wound healing processes or in the placenta. Cancer 
cells have the ability to stimulate the formation of new vessels towards the tumor in 
order to supply itself with nutrients. The idea of anti-angiogenesis as cancer therapy 
was proposed several decades ago (Folkman, 1971). The approval of bevacizumab
(Avastin) for cancer treatment has encouraged researchers to start focusing on 
angiogenesis as a new treatment. Nowadays, it is becoming accepted as a treatment 
for cancer (Ferrara et al., 2005). 
2.2.3    Immunotherapy
Immunotherapy is the use of the immune system to fight cancer. For the past few 
decades, the term immunotherapy has been widely popularized. It was thought earlier 
that the immune system is limited to fighting infections. Recently several important 
discoveries have shown its role in perturbing cancer  progression (Keibel et al, 2009).
           These observations and theories have encouraged scientists to develop this relatively 
new strategy for fighting cancer commonly termed as either active or passive 
immunotherapy. Active immunotherapy can be subdivided into specific and non-
specific therapy. Specific therapy involves designing active immunotherapy agents to 
induce certain immune cells for attacking various antigens on cancer cells
(Lesterhuis et al., 2011). On the other hand, non-specific active immunotherapy 
utilizes the broad activation of the immune system cells by certain agents. These 
6agents include cytokines such as interferon and interleukins (IL-2, IL-12). They 
regulate both adaptive and passive immune systems. Interferon and interleukin have 
been approved by the FDA for certain cancer types, such as the approval of IL-2 for 
renal cell carcinoma and leukemia (Hurley and Chapman, 2005; Yang et al., 2003;
Schuster et al., 2006).
2.2.4 Chemotherapeutic agents
Most of the previously mentioned treatments can be used only for local tumors. Once 
metastasis occurs, a systemic treatment needs to be undertaken which uses 
chemotherapeutics.  These compounds are used to kill cells or stop their growth in 
order to treat cancer. Chemotherapy is widely used in clinical practice. 
Unfortunately, drugs have dose limiting toxicity particularly on cells that divide 
rapidly such as hemopoietic and mucosal cells on the gastrointestinal lining. Of 
particular concern is the effect of cytotoxic chemotherapeutic agents on stem cells. 
Agents with cytotoxic activity function in several ways with DNA being the favorite 
target. Some agents are able to attack DNA and inhibit its replication while others 
can prevent DNA synthesis. However, attacking the mitochondria and mitotic 
spindle are two other mechanisms in which some agents exert their activity (Lind, 
2011). 
Attacking DNA directly is the principal approach amongst most chemotherapeutic 
agents which tend to cause DNA damage and cell death. Agents can achieve this by 
alkylation of key atoms located on the DNA structure thereby forming strong 
7covalent bonds. This mode of action is known to cause potent cytotoxicity in general 
and operates in such drugs as mitomycin, cyclophosphamide, and cisplatin (Lind, 
2011). Other agents perturb the DNA structure through electrostatic forces (Lind, 
2011), intercalation with DNA or binding to DNA grooves. A number of 
chemotherapeutic compounds act by inhibiting the synthesis of DNA such as 
antimetabolites which include methotrexate, 6-mercaptopurine and 6-thioguanine
(Lind, 2011).
2.2.4.1 DNA Groove binders
Apart from alkylation, chemotherapeutic agents can also target DNA via noncovalent 
bonding which can occur at the minor groove region of DNA or in between DNA 
nucleotides. Non-covalent binding to DNA involves electrostatic (e.g., hydrogen 
bonding) and/or van der Waals’ interactions which are the two major forces that 
govern ligand-DNA binding activity.
Sequence specificity is an important criterion when targeting DNA as this will 
reduce the potential side effects caused by chemotherapeutic compounds. A ligand 
needs to cover a minimum of 16 to18 nucleotide binding sites in order to have good 
selectivity at the genomic level (Neidle, 2001). This requirement may present a 
challenge as the larger the molecule the less stable it becomes and the likelihood of 
its contact surfaces to become “out of phase” tends to increase causing a decrease in 
the binding affinity. Sequence selective agents prefer specific DNA sequences 
compared to others. Examples of such agents include pyrrolo[1,4]benzodiazepinone 
8antibiotics (Hurley et al., 1988), netropsin and distamycin (Zimmer and Wahnert, 
1986) and bleomycin (Stubbe and Kozarich, 1987). These agents were found to 
target specific DNA sequences. Netropsin and distamycin prefer AT rich sequences, 
while bleomycin prefers GCs sequences (Povirk et al., 1989).
2.2.4.2 Intercalation
Intercalating agents bind non-covalently and reversibly with nucleic acids. A number 
of intercalating chemotherapeutic agents are now employed clinically for ovarian 
cancer, breast cancers and acute leukemia, while others are still in clinical trials
(Brana et al., 2001). Ethidium bromide, doxorubicin, daunomycin and thalidomide
are examples of DNA intercalators.
Intercalation occurs when a ligand aligns itself between the DNA adjacent bases. 
Usually the compound has a flat planar aromatic structure (Sinha et al., 2006) which 
allows it to slide easily within the narrow space that exists between adjacent DNA 
bases. These agents can cause structural changes to the DNA topology and cause 
genotoxicity (Mortelmans and Zeiger, 2000).
2.2.4.3 Mitotic/spindle and topoisomerase inhibitors 
These agents have the ability to either stabilize the microtubules once they are 
formed or inhibit their formation. Either mechanisms cause a limited flexibility in 
these organelles which results in retardation in chromosomal alignments and 
9inhibition of cell growth.  Examples of these agents are paclitaxel, vincristine and 
vinblastine (Lind, 2011).
Proteins, such as topoisomerases, which are important in cell division, are also
targets for anti-cancer agents. Proteins which play a role in the last stage before cell 
division can be attacked by cytotoxic drugs to inhibit cell division (Lind, 2011).
2.3 Thiol alkylators
2.3.1 Overview 
As explained above, most treatment options involving chemotherapy have serious 
side effects and limitations. Therefore, there is an urgent need to develop novel 
anticancer agents which display high selective toxicities towards neoplasms rather 
than affecting the normal cells. 
Over the last several years we have focused on developing a number of cyclic and 
acyclic conjugated unsaturated dienone derivatives possessing the 1,5-diaryl-3-oxo-
1,4-pentadienyl pharmacophore as tumor selective cytotoxins, Figure 2.1. Generally 
these agents show high selectivity towards cancer cells. The pharmacophore is 
known to interact with cellular thiols (Mutus et al., 1989; Das et al., 2009). Since 
thiol groups are not present in DNA, these agents may lack the ability to interact with 
DNA thereby limiting or eliminating genotoxicity. This property is a significant 
benefit over other chemotherapeutic agents since attacking DNA may result in potent 
cytotoxicity but it may also induce mutations that might be passed to daughter cells. 
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Therefore, having a strategy which would achieve high potency without genotoxicity
is desirable.  
                                                                   1,5-diaryl-3-oxo-1,4-pentadienyl group                                                                                                                                   
Figure 2.1:  Structure of cytotoxic 3,5-bis(benzylidene)-4-piperidones
Designing agents that exert their cytotoxicity in different pathways have shown great 
benefit over agents acting on a single pathway. This can be due to different reasons. 
Targeting different mechanisms would enhance the potency and minimize the chance 
of drug resistance. This is used for various serious illnesses to minimize drug 
resistance development and increase effectiveness (Espinoza-Fonseca, 2006). For 
example, when treating certain bacterial infections, a multi-drug regimen is usually 
used with each agent having its own mechanism of action. The same principle is used 
for cancer treatment. Instead of administering several drugs with different targets, 
having a single drug with different targets might be more convenient and yet 
effective. 
2.3.2 Curcumin
11
Curcumin, (Figure 2.2) is extracted from Curcuma longa Linn roots. The reason 
behind our interest in curcumin is it having similar structural features as our 
compounds. Curcumin contains two 3-aryl-2-propenoyl groups. Figure 2.2 shows the 
pharmacophore of interest contained in the structure. However, the main difference 
found between its structure and our agents is the presence of the piperidine ring in 
our compounds rather than being an acyclic moiety. This heterocyclic scaffold was 
introduced to minimize the flexibility of the acyclic molecules. In addition, the 
presence of nitrogen allows the addition of other side chains to be placed on the 
piperidyl nitrogen atom.
O O
OH
OCH3
OH
OCH3
Figure 2.2: Structure of curcumin
Curcumin has been used for various medical conditions and has an established safety 
profile (Aggarwal et al., 2003). Curcumin is used for such conditions as rheumatoid 
arthritis, liver disease and urinary tract infections (Adams et al., 2004). It is also 
known for its anti-inflammatory and antioxidant properties. Some antiviral, 
antibacterial and antifungal activities were also observed for curcumin (Aggarwal et 
al., 2007).
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Curcumin has also showed some anticancer properties (Sa and Das, 2008) and it’s in 
vitro antiproliferative (Mehta et al., 1997) and apoptotic induction behavior has been 
investigated (Kuo et al., 1996; Liao et al., 2008). In addition, curcumin has showed 
some antiangiogenic effects when tested in vivo and in vitro (Lin et al., 2007). Due to 
these factors, curcumin is of major interest in the battle against cancer. It was 
previously shown that curcumin can exert its biological activity by down regulating 
the expression of several proteins such as NF-kappa B, lipoxygenase (LOX), 
cyclooxygenase (COX2), tumor necrosis factor (TNF) and others. It also inhibits the 
activity of the protein tyrosine kinases c-Jun N-terminal kinase (JNK) and 
serine/threonine kinases (Aggarwal et al., 2003).
However, its high lipophilic nature has limited its use for cancer treatment. It has a 
high first pass effect and therefore low bioavailability (Shoba et al., 1998).
Therefore, it is important to synthesize analogs of curcumin that have the safety 
profile of curcumin but with an improved pharmacokinetic behavior.
2.3.3 Acyclic Mannich bases
The Mannich bases initially prepared in our laboratory have a conjugated styryl
group attached to a keto function. These compounds had only one conjugated 
unsaturated keto group, Figure 2.3. A large number of compounds derived from these 
bases were synthesized with different functional groups. When the acyclic Mannich
compounds were evaluated for biological activity, they showed high cytotoxicity 
against cancer cells (Dimmock and Taylor, 1975; Das et al., 2009). As anticipated, 
they also showed high rates of reactions with a model thioalkyl compound
13
(Dimmock et al, 1980). However, when tested in vivo they had high murine toxicity
(Dimmock et al., 1991) which led to alternate strategies being implemented. 
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Figure 2.3: Structure of acyclic Mannich bases
2.3.4 Cyclic Mannich bases
The incorporation of the acyclic component of acyclic Mannich bases into a
piperidine ring limited the flexibility possible with the acyclic Mannich compounds. 
Such a limitation was hoped to reduce the toxicity probably caused by certain 
conformations of the acyclic agents. Based on such a hypothesis, cyclic Mannich 
bases were synthesized. In addition to the limited flexibility, cyclic Mannich bases 
with two instead of one conjugated styryl keto groups were prepared, vide infra 
(Figure 2.4). Although less cytotoxicity was observed for the cyclic Mannich 
compounds compared to acyclic compounds (Figure 2.4), they still retained 
appreciable cytotoxic activity (Dimmock et al., 1990).
                               
N
H
O
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Figure 2.4: Structure of a cyclic Mannich base (compound 1)
In a detailed study showing the activity of a wide range of compounds, the following 
conclusions were drawn. Compared to compound 1, the lack of flexibility in the 
cyclic analogs lowered the cytotoxic potency; however it also reduced in vivo
toxicity. Cyclic or acyclic compounds having a quaternary ammonium group resulted 
in high potency. However, a disadvantage was their DNA binding capability. This 
could result in mutagenicity (Dimmock et al., 1990).
2.4 Some structure-activity relationships
2.4.1 The central ring
The cytotoxic potencies of some acyclic Mannich bases were higher than curcumin 
itself. Two factors might have affected the potency. The distance between the two 
aryl rings in curcumin is longer than the distance between same aryl rings in 
compound 1 (Adams et al., 2004). In addition, the different substitutions on the aryl 
ring likely have some influence on the activity.  
N
H
O
      
Compound 1
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Compound 3
The replacement of the secondary amino group in compound 1 by a methylene group
in 3 caused a significant decrease in cytotoxic potency. However, 3 was still 
appreciably potent. Compound 1 showed limited activity in vivo but it did not cause 
any animal mortalities. This is probably due to the reduced hydrophilicity compared 
to the acyclic Mannich bases and the accumulation of the agent in adipose tissue 
(Dimmock et al., 1990).
2.4.2 N-Acyl groups
After establishing the activity of the 3,5-bis(benzylidene)-4-piperidones, some side 
chains were proposed to be placed on the piperidyl nitrogen atom. As explained 
above, the high lipophilicity was likely a major reason for the limited in vivo activity. 
Therefore, introducing a hydrophilic group at this site might increase the activity in 
vivo (Lipinski et al., 2001). In addition, it was proposed that these substitutions may
16
interact at an auxiliary binding site. Although this latter hypothesis was not proven, 
such side chains had a significant effect on the potency (Dimmock et al., 1992). For 
example, compound 1 with no N-acyl group and 4 with an added N-acyl group, 
differed significantly in their cytotoxicity against L1210 leukemia cells. Generally, 
N-acyl substitution caused a significant increase in potency on a wide range of cell 
lines. This is probably due to the introduction of an additional conjugated system 
capable of reacting with cellular thiols (Dimmock et al., 2001).
In addition, it was also proposed that the torsion angles (θ) between the aryl ring and 
the adjacent olefinic group has may some have impact on cytotoxic potency. In the 
case of compound 4, the introduction of an acyl group caused about a 24% increase 
in the torsion angle compared to the non-acylated analog (Dimmock et al., 2001).  
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The difference in potencies between compound 5 and 6 (Jha et al., 2007) are as 
follows. When evaluated against human Molt 4/C8 and CEM T-lymphocytes and
murine L1210 leukemia cells, the results have shown the greater potency of 
compounds possessing the Z conformation in compound 5 rather than 6 in which the 
double bond in the N-acyl group adopts the E conformation (Jha et al., 2007). This 
behavior was generally observed in all related compounds. This implies that the side 
chain is in a preferred location in relation to the substituted piperidine ring.
The introduction of the side chain in compound 6 led to a great increase in potency 
compared to compound 1 (Jha et al., 2007). Introducing a nitro group on rings A and 
B also caused a greater increase in potency for compound 7 compared to compound 
6 (Jha et al., 2007). This might be due to two reasons. Introducing an electron-
withdrawing group would result in decreasing the electronegativity of the olefinic
groups adjacent to the aryl rings which might cause a stronger electrophilic attack 
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with thiols. In addition, having a nitro group at such positions might cause some 
hydrogen bond formations with a binding site.
2.4.3 Substitutions on the aryl rings 
Some derivatives of compound 1 were evaluated. All analogs had the same core 
structure except for the substitutions on the aryl rings. The insertion of substituents 
on the aryl ring caused different effects depending on the group added. The chloro
and the methoxy substitutions caused a great decrease in potency when screened 
against HSC-2, HSC-4 and HL-60 cell lines. Other substitutions such as nitro caused 
an increase in potency (Pati et al., 2008).
2.5 NC 2067 and NC 2081
After showing that compounds having the 1,5-diaryl-3-oxo-1,4-pentadienyl 
pharmacophore are potent agents targeting cancer cells, we were interested in 
studying the mechanisms by which these agents exert their biological activity. In this 
regard we chose two representative compounds designated NC 2067 and NC 2081. 
A brief description of their biological and chemical characteristics is presented here.   
As explained above, a wide range of compounds were evaluated and relatively clear
ideas of the structures required for optimal activity were drawn. Therefore, these 
observations lead to the synthesis of compounds NC 2067 and NC 2081. NC 2067
and NC 2081 were evaluated here as two representative agents. Other compounds
with similar structures might have the same or better cytotoxic potencies. However,
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NC 2067 and NC 2081 already have established biological activities. In addition, 
using ChemBioDraw program (version 12), the calculated logP (clogP) value for 
both compounds ranged between 4 and 5 and this is suitable for the biological 
activity (Lipinski et al., 2001). The logP value is used to determine the lipophilicity 
(or hydrophilicity) of a compound. Instead of measuring logP experimentally, clogP 
is determined using some programs. Both agents had no substitutions on the aryl 
rings. We wanted to establish the activity of agents lacking aryl substitutions as a 
first step. Later, other agents with substitutions can be evaluated. Both compounds
have a basic group at their side chain, namely dimethylamino and 4-morpholinyl
substituents. In addition, the torsion angle () between the enone group and the aryl 
rings varied significantly. The effects of these differences were studied.
A detailed study using both compounds and other analogs revealed some interesting
structure-activity relationships. When comparing the activity of NC 2067 with 1, the 
activity of NC 2067 was either double or similar potency compared with 1, 
depending on the cell line. These results encouraged the synthesis of other 
derivatives such as NC 2081, 8 and 9 with different substitutions. The activities of 
these compounds were increased when compared to compound 1 (Das et al., 2007).
NC 2067
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It is noticed that the 4-nitro substitution on the arylidene aryl rings caused a 
remarkable increase in potency in the analogs of NC 2067, 8, 9 and NC 2081
compounds. These latter compounds had similar IC50 values against Molt 4/C8 and 
CEM cell lines despite the difference in their side chains.
In general, potency was favored when a strong basic group was found at the side 
chain and methyl or nitro substituents were placed on the aryl rings. 
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Using different colon cell lines, namely COLO205, HCT-166, HCT-15, KM12, SW-
620 and HCC-2998 the activity of the same compounds was also measured. 
Compound NC 2081 generally showed high potency against some of these cell lines 
and the average IC50 values were lower than that of other compounds including the 
parent compound 1. Unfortunately, compound NC 2067 was not tested on these cell 
lines (Das et al., 2007).
2.6 Mannich–chalcones as a potential prodrugs 
Using a different approach, Mannich bases were combined with a known cytotoxic 
group namely chalcones. The basis for this is the possibility of these agents to 
liberate 3,5-bis(benzylidene)-4-piperidones and a chalcone (Figure 2.5). Both of 
these groups of compounds are known to have cytotoxic properties (Ducki, 2007). 
The complexes formed had only limited potency which could have been due to the
large bulkiness of the molecules or difficulty in penetrating the cell membrane.  In 
addition, the smaller side chains in these compounds did not have strong potency 
either (Dimmock et al., 2002).
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Figure 2.5: The proposed dissociation of a Mannich-chalcone compound to a
cytotoxic Mannich base and chalcone intracellularly.
2.7 Mitochondria
Recently, interest in mitochondrial targeted therapy has been shown. Targeting 
mitochondria can be accomplished via different pathways. For example, targeting the 
mitochondrial DNA, mitochondrial metabolic pathways, mitochondrial membrane 
has been suggested and reveals promising results (Armstrong, 2006). In this work we 
are interested in studying the effect of some compounds on mitochondria in a 
detailed manner. Previously, some work was performed to evaluate some unsaturated 
compounds synthesized in Dimmock’s lab on mitochondrial functions (Dimmock et 
al., 1976). In concert with this, we intend here to further study the effect of 
unsaturated compounds on the mitochondria. Therefore, in this section, a complete 
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description of the mitochondrial function and importance to cancer cells will be 
attempted. This will explain our rationale in targeting this organelle.   
2.7.1 Anatomy and physiology of mitochondria
The mitochondrion is a spherical shaped organelle distributed in the cytosol. It is 
composed of three main parts. First the external mitochondrial membrane encloses 
the mitochondrion large pores that would allow molecules having molecular weights
of 5000 Dalton or less to cross freely from cytoplasm to the inner space. Proteins and 
phospholipids are the main components found in the outer membrane. Second, the 
inner mitochondrial membrane is located beneath the outer membrane. The inner 
membrane is folded to increase the area in which oxidative phosphorylation occurs.
Third, there is space between both membranes which is called the inter membrane 
space.
Figure 2.6: Structure of mitochondria 
The electron transport chain is one of the most important biochemical cascades
occurring in cells. The protein complexes involved in this chain are located in the 
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mitochondrial inner membrane (Rouslin, 1983) A proton concentration gradient 
across the inner membrane is generated while electrons from NADH and succinate
are shuttled from complexes I and II through complex III and finally complex IV. 
Complex V (ATP synthase) uses the difference in proton concentrations to generate
ATP (Ide et al., 2001; Aloysius et al., 2010).
2.7.2 Mitochondria and apoptosis
Apoptosis is a process of programmed cell death in which the cells commit suicide. 
This mechanism is necessary for healing, growth, embryo development and other 
physiological events (Elmore, 2007; Greenhalgh, 1998). Abnormal apoptosis may 
result in various diseases including cancer, neurodegenerative and cardiovascular
diseases and other health problems (Lowe and Lin, 2000; Mattson, 2000). In the past 
decade, researchers have been able to identify the mechanism of apoptosis in detail
(John, 2000). It has been observed that the mitochondrion has a substantial role in 
this process. 
Apoptosis mainly depends on caspases. They are involved in a cascade of events
which happen in a sequential manner so that once activated the cell usually dies. The 
activation of these proteins can occur due to several factors such as DNA damage, 
extrinsic signals, and mitochondrial membrane opening which are all different 
mechanisms for initiating apoptosis. Each one of these processes has the ability to 
stimulate the cascade (Figure 2.6). 
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Figure 2.7: Initiation  of apoptosis. The critical involvement of mitochondria is 
presented here. Apoptosis can be triggered by an intrinsic or extrinsic pathway. The 
extrinsic pathway is activated when ligands bind to Fas receptors causing an 
initiation of a cascade of caspases which will lead to apoptosis. The extrinsic 
pathway may or may not involve the mitochondria. The intrinsic pathway may be 
triggered when damage occurs to an important compartment of the cell. DNA 
damage, high ROS levels, mitochondrial damage by direct insult can all lead to 
intrinsic apoptosis initiation (Green and Reed, 1998).     
Mitochondria play a very significant role in apoptosis. That is DNA damage, 
oxidative stress, Ca+2 overload and ATP depletion (Brookes et al., 2004; Roy et al., 
2008) can all lead to a mitochondrial effect that leads to apoptosis.. These incidents
cause an increase in the mitochondrial membrane permeability (Crompton, 1999)
which results in the swelling of the mitochondrial matrix causing the opening of 
pores through the outer membrane and release of cytochrome c (Green and Kroemer, 
2004). This will result in the activation of all caspases and induces apoptosis. These 
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processes can occur due to covalent binding of compounds with some critical thiols. 
These thiol groups are found in important cysteine residues in proteins regulating the 
permeability of the mitochondrial membrane.  For example, alkylation occurring at 
the thiol group in Cys 56 in the adenine nucleotide transporter  (ANT) protein results 
in the opening of the pores which lead to the entrance of solute (water) causing 
rupture of the mitochondria (Costantini, et al 2000).
The permeability of the mitochondrial membrane is regulated by the permeability 
transition pore (PT) located on the outer membrane of the mitochondria. This pore is 
composed of three main proteins: cyclophilin D (cyp D) found in the matrix,  ANT
found in the inner membrane, and the voltage dependent anion channel
(VDAC) found in the outer membrane (Green and Kroemer, 2004). Figure 2.7 shows
the structure of the pore. 
Figure 2.8: The structure of the permeability transition pore and the mitochondrial 
membranes. The structure includes VDAC, ANT and cyp D. Thiol alkylating agents, 
calcium overload and reactive oxygen species (ROS) are three main agents that
affect the VDAC function (Green and Kroemer, 2004).
28
2.7.3 Differences between mitochondria in cancer and non-malignant cells
In order to design agents that have the ability to target cancer cells only, it is 
important to study the differences between both malignant and non-malignant cell 
types. After studying the biochemistry of cancer and normal cells, a large number of 
differences were noted such as differences in the proteins expressed on the cell 
membrane, inside the nucleus and in mitochondria. Here, I present the most 
significant ones related to mitochondria.  
Cancer cells are able to survive in hypoxic conditions. Several pathways have been 
proposed to accomplish this, for example by activation of the hypoxia-inducible 
factor 1 (HIF-1). These proteins are overexpressed when the cells are in a hypoxic 
environment (Ke and Costa 2006). The proteins cause an increase in the glycolytic 
pathway flux which implies less dependence on oxidative phosphorylation (Ke and 
Costa 2006). Hypoxic conditions also induce the expression of the vascular 
endothelial growth factor (VEGF) (Ke and Costa 2006). This protein causes the 
growth of blood vessels towards the cancer cells. The enzyme hexokinase II also has 
an important role in cancer cells. This overexpressed enzyme catalyzes the rate 
limiting step in glycolysis which phosphorylates glucose. As a result, glycolysis is
over activated in tumors (Chen et al., 2009). In cancer cells, these enzymes are 
associated with the mitochondrial membrane and use the ATP synthesized in the 
mitochondria to produce glucose-6-phosphate. The actions are preferred because 
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cancer cells tend to inhibit the oxidative phosphorylation pathway and induce 
glycolysis (Ralph and Neuzil, 2009).        
Protons are pumped across the inner membrane to the inter membrane space. These 
positively charged particles cause a difference in potential across the membrane 
called the mitochondrial membrane potential (Chen, 1988). This potential is the 
reason for the accumulation of positively charged lipophilic molecules in the 
mitochondrion. Interestingly, the potential across the membrane in cancer cells is 
higher than normal cells by up to 60mV (Chen, 1988; Modica-Napolitano and 
Aprille, 1987). This would cause the attraction of positively charged lipophilic agents 
more towards cancer cells than normal ones. The exact mechanism for such an 
increase in cancer cells is unknown. Some proposed explanations include the 
variations in the respiratory complexes, ATP synthases or even proton conduction.
Lactic acid is the end product of the glycolysis process in the absence of oxygen. 
Cancer cells tend to increase the production of lactic acid by various means
(Yamagata et al., 1998) which are required to kill normal cells and facilitate
metastases (Gatenby and Gillies, 2004). However, in order to survive in such 
conditions, they overexpress proton pumps which keep protons outside the cells. 
Targeting these pumps can caused great damage to cancer cells (Morimura et al., 
2008; De Milito and Fais, 2005).
The lower dependence on the electron transport chain causes oxygen accumulation. 
This can lead to superoxide O2
.- production. Although reactive oxygen species cause
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a great deal of damage to cellular DNA and proteins, cancer cells intentionally keep 
these compounds in high concentrations by the continuous inhibition of oxidative
phosphorylation. This state is called oxidative stress (Pelicano et al., 2004). Reactive 
oxygen species (ROS) are important in cancer cells as they cause further DNA 
mutations whether in the nucleus or in the mitochondria. In addition, ROS functions 
as an intracellular signal (Waris and Ahsan, 2006). ROS should always remain under 
certain threshold concentrations. Exceeding these levels, by for example, inhibiting 
the electron transport chain, will cause cell death by inducing apoptotic proteins. It 
was recognized that agents which cause an increase in the ROS levels induce cancer 
cells to die. Examples of these agents include betulinic acid and menadione (Sasaki 
et al., 2008). These agents can target one of the respiratory complexes, the 
mitochondrial inner membrane or DNA polymerase γ in mitochondria (Ralph and 
Neuzil, 2009).     
A fifth difference between normal and cancer cells is the overexpression of 
antioxidant enzymes (Pelicano et al., 2004; Trachootham et al., 2009) and GST 
(Laborde, 2010) in cancer cells. As explained in the section outlining some of the 
differences between cancer and normal mitochondria, cancer cells are in a state of 
continuous oxidative stress (Schumacker, 2006). Cancer cells manage to adapt 
to such an increased stress by overexpressing antioxidant proteins and peptides such 
as GSH (Pelicano et al., 2004; Trachootham et al., 2009) as well as GST (Laborde, 
2010; Wang et al., 2009; Wang et al., 1997). Their overexpression is at the levels 
required to scavenge the high levels of ROS (Pelicano et al., 2004; Trachootham et 
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al., 2009). The enzyme GST can also help to decrease oxidative stress by reducing 
electrophiles such as aldehydic lipid peroxidation products (Hayes and Strange, 
1995) and by influencing cellular redox homeostasis (Tew, 2007). On the other hand, 
non-malignant cells have normal antioxidant enzyme levels that keep cells in normal 
stress conditions with minimal ROS accumulation (Pelicano, 2004). A slight 
inhibition of antioxidant enzymes will lead to a greater increase in ROS in cancer 
cells (Pelicano, 2004). Unlike cancer cells, a slight inhibition of antioxidant enzymes
in normal cells means that these cells still retain antioxidant enzyme levels 
significantly higher than is needed to scavenge the ROS . Hence inhibition of 
antioxidant enzymes and GST emerges as a potential therapeutic strategy for 
designing anticancer agents (Pelicano, 2004).
The GST enzyme family is present in at least 8 classes (Ricci et al., 2005; Trute et 
al., 2007). The GST enzyme has two main domains. The G-site, which is the 
hydrophilic N-terminal that binds glutathione and the H-site, which is the
hydrophobic C-terminal side that binds to the substrate (Tew and Gate, 2001). A 
tyrosine amino acid is very important for the activity since it accepts a proton 
released by the thiol glutathione. Replacing this amino acid by phenylalanine, for 
example, greatly reduced the activity of the enzyme (Tew and Gate, 2001). 
GST classes differ in their amino acid sequences at the H-site, causing a variation in 
substrate specificities (Tew and Gate, 2001). These differences might be used to 
design compounds that target a specific isozyme.
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Chemotherapy agents were found to have high efficiency but their use is 
compromised by certain shortcomings. One of the main issues regarding the 
available chemotherapeutic agents is the development of resistance. Cancer cells can 
employ different mechanisms to accomplish this. Increasing the expression of the 
targeted protein is one mechanism. A second approach is changing the conformation 
of the protein. The third approach which is the most commonly employed approach 
is the overexpression of the transporters, called ATP-binding-cassettes (ABC), which 
would efflux chemotherapeutics from the cell (Gottesman, 2002).
Despite these issues, chemotherapy remains the most important approach. Therefore, 
restoring the chemosensitivity of tumor cells to chemotherapeutics might be one 
approach to enable these agents to restore their effectiveness. Depending on the 
mechanism of the resistance developed, different approaches have been employed. 
For example, increasing the dose administered may help overcome the problem of 
highly expressed proteins (Basholt, et al 1996). However, this is limited by the 
toxicity seen when high doses are used. Changing the conformation of the protein 
targeted can only be solved by employing different agents that target different 
proteins. This would explain the need for various agents for the treatment of cancer 
(Golan and Tashjan, 2012). ABC overexpression can theoretically be overcome by 
inhibiting these transporters. In order for ABC transporters to efflux a compound, a 
conjugation should occur between the toxin and GSH via GST. Therefore, most 
cancer cell lines overexpress GSTπ compared to normal cells (Laborde, 2010;
Mannervik et al., 1987). GST plays an important role in drug resistance (Cui et al.,
33
2008; Townsend and Tew, 2003; van Bladeren and van Ommen, 1991). GST 
catalyzes the conjugation of GSH with a cytotoxic agent and subsequently the GSH 
conjugate can be effluxed from the cells (Cui et al., 2008). The role of GST in drug 
resistance makes it an attractive chemotherapeutic target (Tew and Gate, 2001;
Townsend and Tew, 2003; Laborde, 2010), and inhibition of GSTπ has induced cell 
death selectively in cancer cells (Cui et al., 2008).
In addition, it has been noticed that the inhibition of the GST enzyme has been 
shown to reduce resistance to chemotherapeutic agents (Balendiran et al., 
2004). Attempts to inhibit these proteins have received great success in vitro
(Balendiran et al., 2004; Cui et al., 2008; Garcia-Rui. et al., 2000; O'Dwyer et al., 
1991). 
Among other sources, ROS is produced in the electron chain transport which is 
located in mitochondria. Therefore, it can be assumed that an increase in 
mitochondrial ROS levels will have its first effect on the mitochondrial membrane. 
GST works in conjunction with other ROS scavengers to reduce the electrophiles 
(including ROS), Figure 2.8.
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Figure 2.9: A general scheme showing the role of GST in detoxification mechanisms.
2.8 GST inhibition
Most tumor cells have higher GST than the corresponding normal cells. Therefore, 
GST inhibition may be more detrimental to tumors than normal cells. One example 
of agents having the potential ability to inhibit GST is those with the α,β-unsaturated 
keto group. 
Our limited knowledge of the active site of GST has made it difficult to design 
agents that selectively and strongly bind to a specific class (Mahajan and Atkins, 
2005). The electrophilic nature of GST substrates is a common phenomenon. This 
electrophilic group attacks the electron rich sulfur atom in GSH. Although GST 
can facilitate this reaction, it might also occur in the absence of the enzyme. As an 
example, chlorambucil forms an ion in cells. This is quenched by GSH which 
attaches to the electron deficient carbonium ion of the drug to prevent it from 
reacting with DNA. The reaction is a typical electrophilic-nucleophilic reaction,
Figure 2.9 (Tew and Gate, 2001).
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Figure 2.10: Mechanism of chlorambucil binding with GSH  
Ethacrynic acid, a loop diuretic (Goldberg, 1966), was found to have GST inhibitory 
activity (Ploemen et al., 1993). It has been shown to inhibit GST –α, -π and -µ. 
Ethacrynic acid can exert such inhibition by binding to the active site, competitively 
and non-competitively. Non-competitive binding occurs when an electrophilic attack 
takes place (Ploemen et al., 1990; Tew et al., 1997; Zhao and Wang, 2006; Tew and 
Gate, 2001). It is also known for its depletion of GSH by conjugating its alkene 
group to the thiol group via a Michael addition, Figure 2.10. Such conjugation may 
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occur spontaneously or mainly with GST catalytic activity (Esterbauer et al., 1991; 
Lagisetty et al., 2010; Zhao and Wang, 2006).
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Figure 2.11: Formation of the complex between GSH and ethacrynic acid (EA)   
In order to study the importance of structural features, the binding of ethacrynic acid 
and its derivatives to GSTπ has been undertaken. It was noticed that the replacement of 
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the chloro atom by methyl, bromo or fluoro substituents at position 3 of the aryl ring did 
not have any effect on the GSTπ inhibition (Zhao and Wang. 2006).
Other agents which inhibit GST are known as glutathione analogs. γ-Glutamyl-
benzylcysteinylphenylglycyl diethyl ester (TLK199) inhibits GST and particularly 
GSTπ. TLK199 can also inhibit the multidrug resistance-associated protein-1 (MRP-1)
(Zhao and Wang, 2006).
Studies of the binding of a series of chalcone derivatives to GSTπ
revealed differences in their binding ability depending on the chemical structure. The 
majority of the compounds inhibited GSTπ. Interestingly, these 
chalcone derivatives have a carboxylic acid group attached at the α position of the 
unsaturated ketone. A Michael addition reaction is expected to occur between the 
olefinic group and the thiol moiety at the H-site of the enzyme (Wang et al., 
2009). From studying the compound-GST interactions, it is clear that strong 
interactions are occurring with the carboxylic acid. Moderate interactions are noted at 
the α,β- unsaturated carbonyl group and the hydrophobic fields (Wang et al., 
2009). Methyl and methoxy groups found at the aryl ring (R1) seem to have minimal 
effect on the activity (Figure 2.11).
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Figure 2.12: Structure of chalcones
Various different Mannich compounds were synthesized and evaluated for their 
activity against GSTπ. Compounds 10a and 10b did not show any significant effect. 
These agents have no 2-alkylaminomethyl group on the cyclopentanone ring (Wang 
et al., 2005). Compounds which have a dimethylaminomethyl and 4-
morpholinylmethyl groups at position 2 of the cyclopentyl ring (11a and 11b, 
respectively) had greater ability to inhibit GSTπ than 10a. This would imply the 
importance of the aminomethyl group on the cyclopentyl ring (Wang et al., 2005).
R
1
R
1
O
Compound 10a: R1= H      10b: R1=CH3
Compounds 11a: R1= dimethylamino    11b: R2= 4-morpholinyl   11c: R3= 1-
piperidyl      11d: R4= 1 –pyrrolidinyl
39
O
N
HCl
         
O
N
HCl
Compound 12a                                                     Compound 12b
Compound 13
Compound 11a with the dimethylaminomethyl group had the highest potency in 
reducing GSH levels compared to derivatives 11b, 11c and 11d which contained 4-
morpholino, pyrrolidino, or piperidino-methyl groups (Wang et al., 2005).  The 
reduction of the ketone group in compound 12a to compound 13 reduced 
the inhibitory activity (Wang et al., 2005).  It is noticed that compounds 10a and 13
have limited ability in inhibiting GSH.  This reveals the importance of the 2-
alkylamino structure and the cyclopentanone group in these compounds (Wang et al., 
2005). Comparing the activities of compounds 11 and 12 reveal that the α,β-
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unsaturated bonds are not crucial for the activity since both derivatives have the same 
GST inhibiting ability (Wang et al., 2005).
2.9. Rationale
The presence of an electrophilic group on the unsaturated compounds presents them 
as a potential target for the thiol group in GST enzyme and GSH peptide (Shiraki, et 
al, 2005). Both are elevated in most cancer cells compared to normal cells. The 
inhibition of GST or the depletion of GSH will indirectly increase ROS levels. In 
addition, the production of ROS may increase by inhibiting one of the electron 
transport chain complexes. These complexes contain some thiol groups (Cortes-Rojo
et al., 2011) which can be alkylated by the unsaturated ketones. Based on this 
rationale, we established our hypothesis and objectives. 
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3. HYPOTHESIS AND OBJECTIVES
3.1 Hypothesis
a. NC 2067 and NC 2081 inhibit GST by acting as a competitive substrate, 
which in turn, depletes cellular GSH content and increases ROS levels. 
b. NC 2067 and NC 2081 exhibit selective cytotoxicity to colon cell lines.
c. NC 2067 and NC 2081 interfere with the electron transport chain to affect 
mitochondrial membrane function leading to cellular death.  
3.2 Objectives
Objective 1: To establish the activity of two agents, namely, [4-[2-
dimethylaminoethoxy]phenylcarbonyl]-3,5-bis[phenylmethylene]-4-piperidone 
hydrochloride (NC 2067) and 1-[4-{2-[4-morpholinyl]ethoxy}phenylcarbonyl]-3,5-
bis[phenylmethylene]-4-piperidone hydrochloride hemihydrate (NC 2081) against 
one colon cancer cell line (HCT-116). This was followed by an evaluation of their
activity against one normal cell line (CRL-1790).   
Objective 2: To evaluate the effect of both agents on the activity of GSTπ.
Objective 3: To investigate the effects of these agents on different mitochondrial 
processes including membrane potential, electron transport chain and mitochondrial 
swelling. 
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4. MATERIALS AND METHODS
HCT-116, CRL-1790 cell lines, McCoy’s and Minimum Essential Media were all 
purchased from ATCC (Burlington, Ontario). 5-Fluorouracil, carbonylcyanide 3-
chlorophenylhydrazone (CCCP) and 2,4-dinitrophenol, sulforhodamine B, JC-1, 1-
chloro-2,4-dinitrobenzene  (CDNB) and DMSO were all purchased from Sigma-
Aldrich, (Oakville, Ontario).
4.1 Anti-proliferation assay
The purpose of this experiment was to determine the potency of both agents on HCT-
116 and CRL-1790 cells. HCT-116 cells used for the cytotoxicity evaluation were
between passages 42 to 44. Passages for CRL-1790 were between 10 and 12. The 
cells were cultured in their respective growth medium supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin. The colon HCT-116 cells were 
cultured in McCoy's medium while CRL-1790 cells were grown in Minimum 
Essential Media.
The method of the National Cancer Institute, USA for determining the IC50 values 
was used (Voigt, 2005).  Cells were plated at 5x104 cell/ml concentration in 100 µL 
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and left for 24h to attach. Then the agents were added using concentrations ranging 
between 0.0095-20 µM for the HCT-116 neoplasm and 0.06-50 µM for CRL-1790 
cells and incubated for 48h. The experiment was conducted in triplicate on three 
separate occasions and standard deviations were less than 10%. The concentration of
DMSO was 1% when HCT-116 was used and 0.5% for CRL-1790. 5-Fluorouracil
(5-FU) was used as a positive control. Concentrations used for 5-FU ranged from 
0.001 to 100 µM.
After 48h the cells were fixed on a plate in each well using 50 µL (50% w/v)
trichloroacetic acid. Cells were incubated for 1 h at 4oC. Then the cells were washed 
and left to dry. Sulforhodamine B (SRB) was used to monitor the change in cell 
viability. It was prepared first in 1% acetic acid at a concentration of 1mg/ml as a 
stock solution. Addition of 100 µL of this solution to cells in each well was 
performed and incubated for 10 min at room temperature. Cells were washed using 
1% acetic acid and left to air dry. The remaining dye was dissolved in 200µL of 10 
mM Trizma base. A Biotek spectrometer was used to measure the absorption at 515
nm. On day one when the drugs were added, one extra plate was treated with 
trichloroacetic acid and sulforhodamine B as indicated previously. This plate will be 
referred to as the Tz plate. It represents the number of cells on the day when the 
drugs were added. Cell growth was then calculated using the following formula: 
                            ODsample - ODTz
%Cell growth =   
                             ODcontrol - ODTz
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Three different cell batches were used and for each batch the experiment was 
conducted in triplicate.   
4.2 Evaluation of ROS levels in cancer cells
The main intention behind performing this assay was to evaluate the effect of both 
agents on ROS levels. Dichlorodihydrofluorescein diacetate dye was used to 
determine such levels. The HCT-116 cells were cultured in 96-well plates. The 
number of cells seeded was 5x103 and left for 24h to attach. Compounds were 
prepared in DMSO at 5 mM concentration. Dilutions were made using media to a 
concentration of 10 µM. Then, 94 µL media were added to 5 µL of the previous 
drug/media solution. By the addition of 1 µL DMSO, the required concentration will 
results in 1% DMSO. Some volumes adjustments were required for each compound. 
Then, the cells were incubated with IC50 concentrations of NC 2067 and NC 2081
(0.571 µM for NC 2067 and 0.503 µM for NC 2081) for 48h. 5-Fluorouracil was 
used as the positive control (Hwang et al., 2007) using its IC50 value of 3.5 µM. 
Subsequently, dichlorodihydrofluorescein diacetate was added and incubated with 
the cells for 30 min at a final concentration of 5 µM. Once inside cells, it is 
hydrolyzed by esterases to produce 2',7'-dichlorodihydofluorescein which is then 
oxidized by ROS to produce a fluorescent product (2’,7’-dichlorofluorecein) which is 
excited at 483 nm to emit light at a wavelength of 530 nm. Higher intensities indicate 
high ROS levels. The media was removed and the cells were washed twice with 100 
µL phosphate buffered saline (PBS). This was performed to remove extracellular 
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probe, and to minimize interference from phenol red. PBS (100 µL) was finally 
added and the fluorescence was measured [excitation at 483nm, emission at 530nm] 
using a Biotek fluorometer. Three different cell batches were used and for each batch 
the experiment was conducted in triplicate.   
4.3 Mitochondrial membrane potential
Our main intention behind this assay is to measure the effect of both agents on the 
mitochondrial membrane potential. For this purpose we used the JC-1 dye. The idea 
behind using this dye is that it forms monomers in cells with low mitochondrial 
membrane potential (unhealthy cells). It forms J-aggregates in the mitochondria of
healthy cells which have a high mitochondrial membrane potential. Therefore, agents 
expected to have an effect of MMP will cause an increase in the monomeric form 
and reduce the J-aggregates. However, the formation of monomers is usually easier 
to detect compared to J-aggregates especially when the decrease in membrane 
potential is relatively minimal (Di Lisa et al., 1995). Three different cell batches 
were used and for each batch the experiment was conducted in triplicate.   
The experiment was conducted based on previous publications (Salvioli et al., 1997; 
Cayman Chemical Company, 2011). HCT-116 cells 5X103 cell/ml were cultured in 96-
well black plates. The lower side was transparent.  After letting the cells attach for 24
h the cells were treated with the IC50 concentrations of NC 2067 and NC 2081. As 
explained above for compound preparation, the same steps were followed here. 
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Compounds were prepared in DMSO at 5 mM concentration. Dilutions were made 
using media to a concentration of 10 µM. Then, 94 µL media were added to 5 µL of 
the previous drug/media solution. By the addition of 1 µL DMSO, the required 
concentration results in 1% DMSO. Some volume adjustments were required for 
each compound. The concentration of CCCP and 2,4-dinitrophenol was 1 µM. They 
were used as positive controls. The JC-1 dye was prepared in the media as a stock 
solution at concentration 20 µg/ml. After 48 h, 10µL of JC-1 were added to each well 
and mixed.  Cells were incubated for 30 min at 37oC and 5% CO2. The cells were 
centrifuged at 400x g and the media was removed. Phosphate buffered saline (PBS) 
(100 µL) was added and again centrifuged. This process was performed twice until 
there was complete removal of the excess dye. 100 µL PBS was added to each well. 
Fluorescence was measured [Ex 485 and Em: 535 for monomeric JC-1 detection] 
using a Biotek spectrometer. 
4.4 GSTπ inhibitory activity
We intended to study to binding ability of both compounds to behave as substrates 
for GSTπ. Our preliminary experiments were performed based on the published 
method (Appiah-Opong et al., 2009). Pure GSTπ was from the Vaccine and 
Infectious Disease Organization-International Vaccine Centre, Saskatoon, 
Saskatchewan (VIDO-InterVac). GSH and CDNB were used to monitor its activity. 
A binding between GSH and CDNB in the presence of GST would result in the 
conjugate form that absorbs UV light at 340 nm. Unfortunately, both NC
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2067 and NC 2081 have maximum absorptions close to a wavelength of 340 nm. 
Therefore, we decided to employ a different approach. First, the absorption of 25 µM 
of NC 2067 and 250 µM of GSH was determined. This results in a GSH:compound 
ratio of 10. Then GST was added to the solution making its final amount 1.2 µg. This 
amount was used based on previous data which showed the optimal rate of 
absorption decrease. The addition of GST was found to increase the volume by 2% 
and it had a minimal effect on the volume increase. The reduction in absorption over 
time was determined for both agents. After the addition of GST, absorption readings 
were taken after 0, 2, 4, 6 and 10 min until no change in absorption was seen. The 
same steps were followed for NC 2081 except that the concentrations used were 
different. The absorption of 30 µM NC 2081 and 300 µM GSH was determined. This 
still gave the same GSH:compound ratio of 10. 
Solutions of GST and GSH were prepared in phosphate buffer pH = 7. Temperature 
was kept at room temperature. The drugs were first prepared in DMSO and the total 
DMSO in the mixture was 1%. The experiment was conducted in triplicate.    
4.5 Oxygen consumption assay
We intend to study the effect of both agents on the rate of oxygen consumption. This 
can be measured by determining the change in oxygen concentration with time. 
After detaching all cells from a flask, 4x106 cells/ml were prepared. The oxygen 
concentration was determined by instilling 1 ml cells in the oxymeter chamber to 
measure the oxygen concentration. The measurement was taken for 2 min.  CCCP 
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was then added at concentration 5 µM. This was performed by preparing CCCP in 
DMSO at concentration 1 mM, then 5 µL was added to cells to obtain the right 
concentration. After observing the oxygen level changes for 5 min, one of the 
compounds was added. This was performed by preparing a stock solution of 1 mM in 
DMSO, then 10 µL to obtain the concentration of 10 µM which was followed by 
another 40 µL of the same stock as explained below. The effect of the agents was 
observed by indicating a change in the oxygen consumption rate. The initial 
concentration of NC 2067 and NC 2081 was 10 µM, subsequently an additional 40 
µM was added. Three different cell batches were used and for each batch the 
experiment was conducted in triplicate.   
4.6 Mitochondrial swelling assay
Our main rationale behind performing this assay was to establish the effect of both 
agents on mitochondrial swelling. This assay depends on the fact that once 
mitochondria swell more UV light passes through. After removing the liver from a 
rat, mitochondria were isolated from the liver using conventional differential 
centrifugation (Kowaltowski et al., 1996). Wistar male rats between 250 and 350g 
weight were used. This work was approved by the University of Saskatchewan’s 
Animal Research Ethics Board, and adherence to the Canadian Council on Animal 
Care guidelines fr humane animal use. Prior to the absorbance measurement, isolated 
mitochondria were diluted in swelling buffer containing 125 mM sucrose, 65 mM 
KCl, 10 mM HEPES, 5 mM potassium phosphate, 1 mM MgCl, pH 7.2, with 5 mM 
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succinate. In order to measure the amount of swelling in the mitochondria, the light 
scattered was determined at a wavelength of 520 nm. Mitochondria were suspended 
to an initial absorbance close to 1.5. A kinetic mode sampling the absorbance every 
10 sec was performed to monitor changes in absorption. Once a steady absorbance 
line was noticed, Ca++ was added to induce swelling in the mitochondria at 
concentration of 50 µM. This resulted in a significant drop in the UV absorbance. 
After confirming the responsiveness of the isolated mitochondria, the effect of our 
compound on mitochondrial swelling was examined. 20µL of the suspension in 1 ml 
resulted in about 1.5 absorbance value.  NC 2067 and NC 2081 were added 
separately at concentrations of 10µM and 50µM. The kinetic mode absorbance 
was recorded for 10 min while observing the change in its values. Two rats were 
sacrificed; the experiment was conducted in triplicate for each liver sample. 
4.7 Statistics
One way ANOVA with Dunnett’s multiple comparison post-hoc analysis was used to 
determine the significance of the effects between treatment groups and control. A p
value below 0.05 was considered significant.  
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5. RESULTS
5.1 Anti-proliferative assay
After conducting the antiproliferative assay we managed to plot a graph describing 
the effect of different concentrations on the proliferation of HCT-116 and CRL-1790. 
Anti-proliferative assay was performed using the SRB dye. Log concentrations were
plotted against the percentage of inhibition for the IC50 calculations. A sigmoidal 
graph was observed. IC50 was determined at the concentration at which the effect is 
half between the maximum (100% inhibition) and the minimum (0% inhibition). 
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This would determine the concentration at which number of cells was reduced by 
half after the incubation period compared to control. 
The anti-proliferative assay reveals the high cytotoxic potencies of both NC 2067
and NC 2081 against the human HCT-116 colon cancer cell line (Figure 5.1). The 
IC50 values were near 0.5 M, and displayed more than 5-fold greater potencies than 
5-FU (Table 5.1). On the other hand, both compounds showed weak growth 
inhibition against normal CRL-1790 cells (Figure 5.2 and Table 5.1). (The cell 
growth inhibition was 31% and 16% at concentrations 25 µM for NC 2067 and NC 
2081, respectively). IC50 for 5-FU against CRL-1790 could not be determined 
because a maximum inhibition of 100% was not reached. These IC50 values were 
used for ROS and membrane potential assays. 
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Figure 5.1: a: The anti-proliferative activity of NC 2067 against HCT-166 cells b. 
The anti-proliferative activity of NC 2081 against HCT-166 cells c. The anti-
proliferative activity of 5-FU against HCT-166 cells. IC50 could not be determined 
form experiment 1. Only Experiments 2 and 3 were used to calculate the average. 
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Figure 5.2: CRL-1790 cell growth inhibition related to concentration. Incubation was 
performed for 48h after which sulforhodamine B SRB was added Concentrations 
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higher than 50µM were not soluble in media and 0.5% DMSO. The experiment was 
performed three times, in each experiment each concentration was made in triplicate
  Table 5.1. Anti-proliferative activities of NC 2067 and NC 2081. IC50 of both 
agents on HCT-116 cells ranged from 0.5 to 0.6 µM. IC50 of both agents on CRL-
1790 was above 25µM.   
Compound IC50 µM+SD*
HCT-116 cell 
line
CRL-1790 cell 
line
NC2067 0.571+0.105 > 25
NC2081 0.503 +0.081 > 25
5-FU 3.558+1.06 >25
* SD= Standard deviation 
5.2 ROS evaluation
The increase in ROS levels was apparent after cells were treated to both agents. This 
was concluded after observing an increase in fluorescence intensities of 
Dichlorodihydrofluorescein. The average increase of fluorescence intensities 
represents an increase in ROS. One may conclude from Table 5.2 that both agents 
caused a 3-7 fold increase in fluorescence intensity when HCT-116 cells were treated 
with the IC50 concentrations of NC 2081 and NC 2067 for 48 h. The difference in 
ROS induction between each compound and DMSO was significant with a p value 
less than 0.05 (Appendix 1). It should also be noted that the number of cells was 
reduced by half after the incubation, therefore, the intensities (fluorescence units) 
were doubled for all three agents to be comparable with the number of cells in the 
DMSO condition.
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Table 5.2. Effect of cytotoxic agents on ROS levels in HCT-116 cells. Both agents, 
and 5-FU were able to induce ROS about 3-7 fold. The average increase of 
fluorescence intensities represents an increase in ROS. 5-FU was used as a positive 
control. The value of p was less than 0.05 when the effect of each agent was 
compared with DMSO. Each experiment was conducted in triplicate.
Compound Average 
intensities+SD*
NC 2067 9946+252
NC 2081 5036+994
5-FU 7298+560
DMSO 1387+55
* SD= Standard deviation 
5.3 Mitochondrial membrane potential
After performing this assay we were able to observe the effect of agents on MMP. 
Table 5.3 reveals the ability of both the agents to increase the levels of the 
monomeric form of JC-1 in HCT-116 cells about 2 fold which indicates that NC 
2067 and NC 2081 reduce the mitochondrial membrane potential in these cancer 
cells. The p value was found to be less than 0.05 for all agents when compared with 
DMSO. The monomeric form was measured at Ex of 485 nm and Em of 535 nm. 
The monomeric form tends to accumulate in unhealthy cells with lower 
mitochondrial membrane potential. For NC 2067 and NC 2081, the number of cells 
were reduced by half after 48 h. Therefore, the intensities were doubled for both 
agents to be comparable with the number of cells in the DMSO condition.
Table 5.3. Evaluation of the mitochondrial membrane potential of HCT-116 cells 
after treatment with NC 2067, NC 2081 and positive controls CCCP and 2,4-
dinitrophenol.. JC-1 was added after incubation with the test compound for 48 h. The
p value when comparing between both agents and DMSO was less than 0.05.  Each 
experiment was conducted in triplicate. 
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Compound Average+SD*
NC 2067 6074+456
NC 2081 6376+509
2,4-dinitrophenol 7541+769
CCCP 7277+519
DMSO 3069+20
*SD= Standard deviation
5.4 GST activity
After conducting the explained experiment it was revealed that both compounds NC 
2067 and NC 2081 behave as substrates for GSTπ. The top curve indicates the 
absorption of one compound alone. The addition of GSH and GSTπ caused a great 
drop in absorption. Decrease in absorption continued when it was measured every 2 
min. This reduction was stopped after 10 min indicating that agent’s concentration is 
steady. The decrease seen at the beginning implied a decrease in drug concentration 
caused by the removal of agents or binding molecules with other compounds (GSH). 
Such binding will cause a change in chemical structure and therefore change in 
λmax. The concentration of both compounds was not affected by the addition of 
GSH nor GST individually, and in these conditions the compounds were stable
during the period of the experiment.   
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Figure 5.3: Absorbance for NC2067 with time after the addition of GSH and GST. 
The decrease in absorbance at ~314 nm implies a decrease in concentration which is 
the result of the attachment of the agent with GSH. GSTπ was required for this 
attachment. A decrease in absorbance was measured with time until about 10 min. 
Figure 5.4: Absorbance for NC2081 with time after the addition of GSH and GST. 
The decrease in absorbance at ~319 nm implies a decrease in concentration which is 
the result of the attachment of the agent with GSH. GST was required for this 
attachment. A decrease in absorbance was measured with time until about 10 min. 
5.5 Oxygen consumption assay
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Measuring the oxidative phosphorylation activity can be conducted by determining 
the changes in oxygen concentration over a period of time. The measurement of 
oxygen concentration over time determines the rate of concentration change. This 
value is represented by the slope produced when the oxygen concentration is plotted 
against time. Treating the cells with 5 M CCCP caused an increase in the oxygen 
consumption rate from 2 to 7 M/min (Figure 5.5 and Table 5.4). However, adding 
NC 2067 or NC 2081 caused a significant inhibition in the oxygen consumption rate.
The addition of both agents was conducted in two phases. The first phase involved
the addition of 10 µM. This caused about a 50% decrease in the respiratory rate for 
both agents. When 40 µM were added, the rate decreased by about 50% again for 
both agents. The oxygen consumption of untreated cells was measured for about 10 
min. The rate was steady for that period and equaled 2 M/min. The addition of 
CCCP caused about a 4 fold increase in the consumption rate. 
Figure 5.5: Oxygen consumption with the addition of CCCP, NC 2067 and NC 2081. 
The purple line represents the cells alone respiration. CCCP was added at 5 µM at 
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the beginning as indicated in the figure. Both agents were added 2 min after the 
addition of CCCP at concentrations of 10 µM as indicated in the figure. After 
recording the oxygen consuption for 2-3 min, another 40 µM of each agent was 
added making the final concentration 50 µM.    
Table 5.4: Oxygen consumption in response to the addition of compounds NC 2067
and NC 2081. The inhibition or stimulation percentage compared to the column 
before the addition. The addition of CCCP caused an increase in oxygen 
consumption rate while the addition of the compounds caused a decrease in the rate. 
Percentage of inhibition after CCCP was added was related to the rate when nothing 
was added. 
Addition of CCCP (5 µM)
(% stimulation +S.D.)
Addition of NC2067 
(10 µM) (%  inhibition
+S.D.)
Addition of NC2067 
(50 µM) (% inhibition
+S.D.)
Percentage 
change
69.4+12.6 51.54+8.52 27.65+3.04
Addition of CCCP (5 µM)
(% stimulation +S.D.)
Addition of NC2081 (10 
µM)
(%  inhibition +S.D.)
Addition of NC2081 (50 
µM)
(% inhibition +S.D.)
Percentage 
change
55.93 + 2.69 59.52+6.68 31.56+13.88
5.6 Mitochondrial swelling assay 
Compound NC 2081 produced some swelling of mitochondria when treated with 10 
and 50 µM of the compound (Figure 5.6). This was represented by a decrease in 
absorption with time. The decrease in absorbance was measured until a steady line 
was seen. The absorbance was taken every 10 sec for about 10 min. The addition of 
10 and 50 µM of NC 2081 caused swelling as shown in the figure. The addition of 
the higher concentration caused about 2 fold more than the lower one. A decrease in 
absorbance from 1.5 to 1.3 for the higher concentration was noted.  A decrease of 0.1 
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absorbance unit was observed when 10 µM was added. On the other hand, compound 
NC 2067 produced swelling only at a concentration of 50 µM (Figure 5.7). The 
absorbance decreased from 1.5 to 1.37 over the time period measured. No change in 
absorbance over this time period was seen using 10 µM NC 2067. This would imply 
that NC 2067 has minimal effect on mitochondrial swelling. A solution of Ca+2 ions 
was used as a positive control at 50µM concentration (Figures 5.6 and 5.7). This 
caused a significant decrease in absorbance implying that a rapid and substantial
amount of swelling was induced.
Figure 5.6: Mitochondrial swelling after the addition of NC 2081 and Ca++. The 
compound was added after measuring the steady absorbance of mitochondria for 
about 20 to 40 sec. 
60
Figure 5.7.: Mitochondrial swelling after the addition of NC 2067 and Ca++. The 
compound was added after measuring the steady absorbance of mitochondria for 
about 20 to 40 sec. 
6. DISCUSSION 
The main objective of our laboratory is to synthesize anticancer agents that interact 
with thiols rather than having DNA as the main target as is the case with many 
contemporary antineoplastic drugs. The compounds of major interest in our 
laboratory contain the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore which are 
believed to have a high potential for targeting thiols which may include GST and 
GSH (Das et al., 2007). Therefore, we conducted a series of experiments to 
determine some of the modes of action of NC 2067 and NC 2081. Both compounds 
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have the pharmacophore of interest with different N-acyl side chains. We chose these 
compounds because they possess potent cytotoxic properties towards a number of 
cancer cell lines (Das et al., 2007).
Cancer cells tend to shift their energy dependency to glycolysis (Van der Heiden et 
al., 2009). This change in metabolism reduces the efficiency of respiratory oxidation 
which in turn results in ROS accumulation (Hileman et al., 2004). Malignant cells 
have managed to adapt to such an increase in elevating ROS concentrations by 
overexpressing GST (Mannervik et al., 1987; Laborde, 2010), GSH and antioxidative 
enzymes (Estrela et al, 2006). These proteins act in conjunction with other 
antioxidants as electrophilic and reactive oxygen species scavengers (Figure 2.6). 
However, to maintain the state of oxidative stress in cancer cells, antioxidative 
enzymes are found in certain levels which cause the ROS concentrations to remain 
relatively high. High ROS levels are required for cell proliferation and signaling in 
tumors. However, extremely high concentrations of ROS can initiate apoptosis 
(Trachootham et al., 2009;Toyokuni et al., 1995). An increase in ROS levels is also 
expected to have an immediate effect on the mitochondrial membrane.
In general, we have evaluated the effect of both agents on cell proliferation, ROS 
levels, mitochondrial membrane potential and GST. In addition, we also determined 
the effect of both agents on cellular oxygen consumption and mitochondrial swelling.
The anti-proliferative results were anticipated because previous reports have
established the high potency against cancer cells for NC 2067 and NC 2081 and 
some related compounds (Das et al., 2007). 
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This antineoplastic effect might be the result of targeting GST. As explained above, 
high GST and GSH concentrations compared to ROS levels in normal cells allow a 
slight reduction in GSH’s levels without affecting ROS concentrations. This is 
presumably because normal cells have low oxidative stress conditions (Schumacker, 
2006). On the other hand, cancer cells remaining in a continuous oxidative stress 
have sufficient GSH and antioxidative enzyme concentrations to scavenge ROS. 
Therefore, a slight reduction in GSH would render the ROS levels higher than the 
cancer cells can accomodate. As a result, the mitochondrial membrane potential in 
tumors will be reduced to levels at which apoptosis can be initiated.
6.1 Anti-proliferative determinations 
As indicated previously, both agents cause potent inhibition of the growth of HCT-
116 cancer cells. They also had a much less cytotoxic effect on normal cells (CRL-
1790) with an IC50 value above 25 µM. The exact IC50 figures for the normal cell line 
were not achievable since a plateau at high concentrations was not observed. That is, 
in order to obtain an IC50 a complete sigmoidal curve should be present which would 
have a steady mimimum at inhibition and a steady maximum inhibition. As shown in 
Figure 5.1 at high concentrations the effect of the compounds was not maximized. 
Higher concentrations would be necessary to in order to establish such relationship.   
With the normal cell line, the maximum concentration used was 50 µM. Higher 
concentrations of solutions were not possible when a maximum of 0.5 % DMSO was 
used. This concentration of DMSO was used after optimization experiments 
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conducted with different DMSO concentrations revealed that 0.5% DMSO did not 
affect the viability of the cells.     
Although the SRB assay is widely used it has some disadvantages. The SRB dye is 
used to measure the proteins in cells. Thus, the exact number of healthy cells cannot 
be determined using this dye. For example, proteins in cells going through apoptosis 
might be detected and show a falsely high number of living cells.    
6.2 GST and GSH
Agents with high potency on cancer cells exert their action by various mechanisms. 
Our first intention was to provide more evidence to our hypothesis in which such 
specificity is mainly caused by inhibiting key mechanisms critical in cancer cells and 
not normal ones. Therefore, we first showed the ability of agents to act as substrates 
for GST activity and thereby decrease GSH levels.   
In order to evaluate our hypothesis, we determined the effect of both agents on 
GSTπ, a class that is usually overexpressed in cancer cells (Mannervik et al., 1987; 
Laborde, 2010). The results revealed the ability of GST in conjugating both agents to 
GSH. This observation implies that both compounds behave as substrates for GSTπ. 
Also, as substrates of GST these compounds would deplete GSH and render the cells 
less protected from reactive species. This effect will contribute to an increase in ROS 
levels leading to mitochondrial membrane potential reduction and cell death.
The results show a reduction in the absorbance of the compounds until a certain 
absorbance is reached. Not reaching an absorbance of zero, despite the use of 1:10
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ratio of GSH:compound, would imply the formation of a GS-compound complex,
which might inhibit the enzyme by product inhibition. This result was also observed 
for other compounds such as ethacrynic acid (Awasthi et al., 1993). To confirm this 
behavior, the GS-compound complex should be synthesized and evaluated against 
GST activity. The synthesis of the GS-compound complex may reveal that the 
compound is likely to bind to the enzyme’s H-site. 
One of the main disadvantages of the method used here was the lack of the ability to 
determine the exact amounts of the products formed. Determining these data would 
enable us to quantify the binding strength and obtain other pharmacokinetic data. 
Two agents were tested in my work which are representative of several series of 1-
acyl-3,5-bis(benzylidene)-4-piperidones. It is conceivable that other members of this 
group of compounds will also react with GSH and GST in the same way. However, 
other factors such as the bulkiness and accessibility of the 1,5-diaryl-3-oxo-1,4-
pentadienes to interact with the binding site will also influence the rate and extent of 
thiol depletion. 
Both agents did not bind with GSH without the presence of GST. This would imply 
that GST is required to activate GSH or the compound in order to link both together. 
GSH is known to be activated by deprotonating the thiol group in the portion of GSH 
leaving a negatively charged sulfur atom. The electrons in α,β-unsaturated ketones 
are polarized as shown in Figure 6.1 and hence nucleophilic attack occurs at the beta
carbon atoms of the cytotoxin. 
  
65
Figure 6.1: The reaction of thiols with α,β-unsaturated ketones
The main limitation to this technique as explained previously is the overlapping of 
the absorption peaks with each other. One other issue is the presence of all of the 
compounds (reactants and products) in the same vessel. Therefore, the exact effect of 
each compound is not achievable. A solution to this problem might be using HPLC 
after the reaction had reached equilibrium. Each separated fraction can then be 
analyzed. 
In addition, the possibility of the binding between GST and the compounds was also 
studied. When GST and the compounds were both incubated for 20 min, no decrease 
in the absorption of the compounds was seen. This observation confirms that the 
compounds do not bind with GST covalently. Non-covalent interactions do occur 
because the enzyme is able to combine the compounds with  GSH.   
In summary, we have shown the conjugation of the compounds was obtained only 
after the addition of both GSTπ and GSH which may be explained as the catalytic 
ability of GST in binding GSH with the compounds. Therefore, the use of LC-MS is 
recommended for the exact detection of the products.   
6.3 Reactive oxygen species 
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About a 3-7 fold increase in ROS was measured after the treatment of HCT-116 cells 
with both agents. One reason for this increase in ROS levels may be due to the 
depletion of GSH when acting as a substrate of GST. However, another factor which 
may lead to ROS induction is the inhibition of the oxidative phosphorylation 
pathway (Mattiazzi, el at, 2004). Therefore, the possible effect of both agents on 
these pathways is explained in the next sections. 
ROS elevation is linked to several consequences. These molecules have the ability to 
react with macromolecules in cells which would damage proteins, DNA and induce 
some apoptotic signals (Benhar et al., 2001; Benhar et al., 2002). Because ROS is 
mainly produced by respiration processes, it is reasonable to assume their effect will 
initially be exerted on mitochondria. In the present case, we used the dye 
dichlorodihydrofluorescein diacetate to detect ROS. 
The IC50 values of both compounds against HCT-116 were used throughout the mode 
of action investigations, unless indicated otherwise. After 48 h the number of cells 
was reduced to half in the treated wells compared to DMSO treated. Therefore, after 
measuring the fluorescence in each well, the value was multiplied by 2 for the treated 
wells to compensate for the drop in cell number.
One major limitation of this technique is the inability to distinguish between the 
different types of ROS (H2O2, O-, OH.) although it is claimed that the 2’.7’-
dichlorodihydrofluorescein assay has some specificity towards H2O2 (Rhee et al, 
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2010) . In our case, we were interested in knowing the effect of the agents on ROS in 
general.
6.4 Mitochondrial membrane potential
The MMP is the result of the difference between the proton concentrations across the 
inner mitochondrial membrane. Protons are highly concentrated in the inter 
membrane space compared to the matrix. This difference is caused by pumping 
protons into that space by respiratory complexes (I-IV). This potential is used by 
complex V (ATP synthase) to synthesize ATP when using the energy derived by a 
downhill flow of protons (Chen, 1988). This potential is critical for cellular survival 
for several reasons. As explained previously, the synthesis of ATP directly depends 
on the MMP. Reducing the MMP might cause a reduction in ATP production and be 
the reason why bringing MMP to zero will induce apoptosis. On the other hand, 
affecting the electron flow by attacking one of the complexes directly will cause a 
blockage of flow to complex IV leading to oxygen accumulation which causes ROS 
production (Ricci et al, 2003; Chen et al, 2007).    
The MMP is known to be affected by various causes. ROS leads to direct damaging 
effects on membranes, opening of the MPT pore and collapse of the MMP (Vercesi 
et al., 1997). ROS can also cause mutations in mitochondrial DNA which would 
cause structural deformities in membranes (Ehlers et al., 1999).
After showing that both agents were able to induce ROS, we wanted to determine if 
such increases would cause any effect on the MMP. Our results have shown some 
ability for both agents to reduce the MMP. Because our results suggest that the 
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agents can directly deplete GSH, it can then be proposed that the consequent increase 
in ROS caused the effect on mitochondrial membrane potential. 
JC-1 was used as a dye to measure the membrane potential. Healthy cells have a high 
MMP and in such cells, JC-1 forms J-aggregates that are excited and emit light at 
wavelengths of 560 nm and 595 nm, respectively. In unhealthy cells with altered 
MMP, JC-1 forms monomers that are excited and emit light at wavelengths of 485 
nm and 535 nm, respectively. 
Other dyes such as DiOC6(3) and rhodamine 123 can be used for the same purpose. 
However, JC-1 seems to be more selective towards changes in the MMP rather than 
the cellular membrane potential (Salvioli et al., 1997). Despite this advantage, JC-1 
had low solubility in media which causes difficulty in dissolving it while it is 
incubated with cells. One other issue is the low sensitivity of the monomeric forms. 
In other words, in order to form the  J-aggregates, MMP should be greatly decreased 
(Di Lisa et al., 1995). In our results, the J-aggregates form was not altered perhaps 
because of the lack of any large drop of the MMP. 
Carbonyl cyanide m-chlorophenylhydrazone (CCCP) and 2,4-dinitrophenol were 
both used as positive controls. Both agents are uncouplers that cause a decrease in 
the difference in the proton concentrations. This is achieved by the attachment of the 
agents to a proton from the intermembrane space and bringing it across the inner 
membrane to the matrix (Korde et al., 2005). Performing this would bypass the ATP 
synthase producing heat rather than ATP. 
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6.5 Oxygen consumption
After evaluating the effects of the agents on cell proliferation, ROS and MMP, we 
wanted to determine if there was any effect of these compounds on oxygen 
consumption. In mitochondria, ROS are mainly produced by the inhibition of 
oxidative phosphorylation. Hence the effect of the agents on oxidative
phosphorylation was a reasonable approach. 
Using an oxymeter, the levels of oxygen in solution were measured. The oxygen 
consumption rate was increased by the addition of a known uncoupler (CCCP). The 
subsequent addition of agents caused an inhibition in oxygen consumption. This was 
determined by the decrease in the oxygen consumption rate. The range of reduction 
in phosphorylation is 2 to 3 fold, depending on the agents and concentrations. 
These results imply that both agents inhibit the electron transport chain. The exact 
protein(s) inhibited is/are yet to be identified. 
Complex I is believed to be the rate limiting step in the electron transport chain 
which can be inhibited by rotenone. It reduces NADH to NAD+ in the first step in 
the chain. When inhibited by rotenone (Li et al, 2002) the entire chain is not 
completely blocked. This complex, in addition to complex III, is believed to be the 
main generators for ROS (Turrens, 1997). Complex II is another electron supplier 
which also delivers an electron to complex III. The reduction of succinate to 
fumarate accompanies this process. 
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Complex III is oxidized when it receives electrons from the previous complexes (I 
and II) and delivers these electrons to complex IV via cytochrome c. Antimycin and 
cyanide are two agents that inhibit complex III and IV, respectively (Huang et al., 
2005; Ricci et al., 2003) Inhibiting the oxygen consumption causes the cessation of 
ATP production and cell death. In addition, increases in ROS levels can be seen 
when some complexes are inhibited, Figure 6.2 shows these processes. 

Figure 6.2: Structure of the electron transport chain in the mitochondria. Rotenone, 
malonate, antimycin, cyanide and oligomycin are inhibitors and are shown near the 
protein they block. Δψ: mitochondrial membrane potential (Ricci et al., 2003).
Using this method we will not be able to determine which complex is inhibited. 
Other techniques such as measuring specific complex activities are needed for such a 
purpose.
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6.6 Mitochondrial swelling assay
Inducing mitochondrial swelling can be achieved by the alkylation of the sulfhydryl 
groups on the mitochondrial membrane (Costantini et al., 2000). In addition, swelling 
can occur as a result of GSH depletion and ROS elevation (Galindo et al., 2003).
Since both agents have the ability to deplete GSH and elevate ROS, we wished to 
determine the effect of these agents on mitochondrial swelling. As explained 
previously, NC 2081 had some mitochondrial swelling induction ability at 
concentrations of 10 µM and 50 µM. NC 2067 has an effect on mitochondrial 
swelling when 50 µM concentration was used but no effect at a concentration of 10 
µM. The concentrations used were quite high since the incubation time is only 10
min. The ability in causing swelling was also observed previously for related 
compounds (Das et al., 2008). 
Apparently, inducing mitochondrial swelling by depleting GSH gives only a weak 
response. On the other hand, alkylation of the mitochondrial membrane pore leads to 
a opening which causes significant swelling. Alkylation occurs at the thiol group in 
Cys 56 in the ANT protein. Examples of such thiol cross-linking agents are 
dithiodipyridine, bismaleimidohexane and others. Although some of these agents 
lack the unsaturated keto group, they have the ability to oxidize the critical amino 
acid (Cys 56) in ANT. 
Ca+2 is known as a mitochondrial swelling inducer (Chappell and Crofts, 1965). Its 
role in mitochondria has been established for the past two decades. Transporters to 
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organize the entry to and from the mitochondria include Ca+2 uniporter, Na+/Ca+2
carrier, Na+/H+ antiporter and Na+-independent efflux of Ca+2. High Ca+2 
concentrations can induce the opening of the permeability transition pore (PTP) 
(Picard et al., 2008). 
The mechanism in which the PTP is opened is not fully understood. Cyclophilin D is 
believed to bind with the pore protein in the ANT matrix side which would open the 
pore protein (Woodfield et al, 1998). Ca+2 is one substance that induces cyclophilin 
D to bind to the PTP. Opening these pores allows water to flow in and cause 
mitochondrial swelling which, depending on how severe, will cause rupture of the 
mitochondrial outer membrane. 
Both cytotoxins inhibited the respiratory chain. As previously indicated, neither 
agent showed the ability to bind to the sulfhydryl group on GSH without GST as the
catalyst. GSH and the sulfhydryl groups in the mitochondrial membrane might have 
different characteristics. However, it is still reasonable to suggest the ability of the 
agents to bind with the mitochondrial membrane.
The difference in activity between both compounds can be attributed to the following 
reasons. Both compounds contain a nitrogen base in their side chains. However, the 
basicity of the nitrogen atom in NC 2067 is more than 100 fold greater then the 
basicity of the morpholine group of NC 2081. As shown in the figures presenting the 
structures of NC 2067 and NC 2081, the torsion angels between the aryl rings and 
the olefinic carbon are different in each compound. That is 1 and 2 in compound 
NC 2067 are +17 and -42 respectively. However, in NC 2081, 1 and 2 when 
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measured simply by using Polymol program are-18 and -27. Such differences might 
also have some effect of the binding of agents to certain proteins affecting the 
membrane permeability. However, these differences in structure did not cause major
differences in activity in the other assays reported here.    
6.7 Future work
For future work, it would be interesting to establish whether a wider range of analogs 
act by the same mechanisms. This may suggest that not only these two compounds 
are able to cause these effects, but all compounds possessing the 1,5-diaryl-3-oxo-
1,4-pentadienyl pharmacophore would act in the same manner. In addition, a strong 
structure-activity relationship may be established. The GST and GSH results should 
encourage us to study the kinetic studies in depth. The use of HPLC and mass 
spectrometry are two techniques proposed to isolate all compounds and then 
determine the quantity of each.
These results showed that these agents have some effect on mitochondria; however, 
the exact mechanism of involvement is yet to be addressed. Different pathways can 
be affected and result in cell death. For example, affecting an electron respiratory 
complex is one mechanism for cell death. The exact complex inhibited should be 
determined. In addition, the influence of other mechanisms may involve the 
alkylation of ANT, damaging mitochondrial DNA and affecting the Krebs cycle. The 
effect of these compounds on these mechanisms has not been evaluated yet. 
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After the evaluation of the effect of both compounds, NC 2067 and NC 2081, other 
compounds, possessing the same pharmacophore, will be evaluated against the same 
mechanisms. This will reveal if these pathways are affected by compounds having 
the same structures.   
Later, after confirming the activity of these compounds  in vitro we would like to 
evaluate their activity  in vivo. A previously evaluated compound possessing the 
same pharmacophore was evaluated and was unsuccessful in vivo (Dimmock et al., 
1990). However, compounds NC 2067 and NC 2081 have not been evaluated in 
vivo. These compounds have different physicochemical properties which would 
encourage the evaluation in mice. For example, they have lower logP than the 
previously evaluated compounds. This would improve the biodistribution rather than 
residing in the adipose tissues. In addition, both compounds lack the quaternary
ammonium ion which is probably the main reason for the neurotoxicity seen in 
previous evaluations. 
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7. CONCLUSIONS
NC 2067 and NC 2081 possessing the 1,5-diaryl-3-oxo-1,4-pentadienyl 
pharmacophore inhibit the proliferation of HCT-116 cancer cells while exerting 
minimal effect on normal ones. The IC50 values for both agents ranged from 0.5 - 1
µM and above 25 µM for cancer and normal cells, respectively.  One proposed 
mechanism of action is their being substrates of GST and thus depleting GSH levels. 
This will cause two main actions. The first is the increase in ROS levels and the 
second is the lowering of the cancer cell’s ability in developing resistance to certain 
chemotherapeutics. Both agents were able to increase ROS levels by 3-7 fold.  
A second mechanism which might also lead to the induction of ROS levels is the 
inhibition of the electron transport chain which was determined as the inhibition of 
oxygen consumption. Both agents inhibit oxygen consumption implying that this 
might be another mechanism for ROS induction. 
The increase in ROS levels caused by both agents is one mechanism to decrease the 
potential around the mitochondrial inner membrane. As explained, these agents seem 
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to increase ROS by two mechanisms, the first is the decrease in GSH and the second 
is the blockage of oxygen consumption. These mechanisms were proved 
experimentally and seem to be the most likely pathway for ROS increase. In 
addition, it is reasonably assumed covalent interactions are not happening between 
the agents and the mitochondrial membrane.
NC 2081 had mitochondrial swelling induction ability at a concentrations of 10 µM 
and 50 µM. NC 2067 has an effect on mitochondrial swelling when 50 µM is used 
but no effect at a concentration of 10 µM. The increase in ROS levels might cause 
some mitochondrial swelling but in this case the increase was not severe enough to 
produce a large effect. 
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APPENDIX
Appendix 1: Table showing post-hoc results when comparing the effect of each 
compound and the effect of DMSO on ROS levels. Significant effect was seen when 
these comparisons were made. GraphPad Prizm program was used to preform one 
way ANOVA -Dunnett’s multiple comparison test.
   
Dunnett's Multiple Comparison 
Test Mean Diff. Significant? P < 0.05? 95% CI of diff
DMSO vs NC2067 8559 Yes 9684 to 7434
DMSO vs NC2081 3500 Yes 4625 to 2375
DMSO vs 5-FU 5911 Yes 7036 to 4786
Appendix 2: Table showing post-hoc results when comparing the effect of each 
compound and the effect of DMSO on MMP. Significant effect was seen when these 
comparisons were made. GraphPad Prizm program was used to preform one way 
ANOVA -Dunnett’s multiple comparison test.
Dunnett's Multiple Comparison Test Mean Diff. Significant? P < 0.05? 95% CI of diff
DMSO vs NC2067 -3005 Yes -4221 to -1789
DMSO vs NC2081 -3307 Yes -4523 to -2091
DMSO vs 2,4-Dinitrophenol -4472 Yes -5688 to -3256
DMSO vs CCCP -4208 Yes -5424 to -2992
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